Background: Anti-tumour necrosis factor [TNF] therapy in combination with thiopurine is the most effective strategy for Crohn's disease, but raises safety concerns. Methods: In a retrospective multicentre study, we investigated long-term outcome of patients starting anti-TNF monotherapy for Crohn's disease and investigated whether introducing an immunomodulator in patients losing response to anti-TNF monotherapy is effective for resetting immunogenicity. . Cumulative probability of remaining on anti-TNF therapy was 57.9% at 5 years among the 297 patients not starting an immunomodulator during follow-up. Conclusion: An immunomodulator was initiated in 15% of patients with Crohn's disease starting anti-TNF monotherapy. Independent predictors of immunomodulator initiation were infliximab use and second-/third-/fourth-line anti-TNF therapy. Resetting immunogenicity with an immunomodulator was effective in half of patients in a sub-study. Persistence of anti-TNF treatment at 5 years was observed in half of the 297 patients not starting an immumodulator in a real-life setting.
to be effective in CD, namely adalimumab, certolizumab pegol, vedolizumab, and natalizumab. A recent French nationwide survey among private gastroenterologists found that the use of combination therapy is very low, representing only 4.5% of IBD patients in a reallife setting. 5 This may be partly explained by safety concerns such as lymphoma risk associated with the use of combination therapy. 6, 7 By contrast, there is no increased risk of malignancy among IBD patients treated with anti-TNF monotherapy except for skin cancers. 6, 7 Anti-TNF monotherapy may be associated with a better safety profile than combination therapy, especially in some specific patient populations such as young males and elderly people. 6, 7 Accumulating evidence indicates that combination therapy reduces immunogenicity of anti-TNF therapy and improves trough levels in IBD patients. 6, 7 Interestingly, a recent pilot study suggested that the addition of an immunomodulator to anti-TNF therapy might be effective in patients who have lost response to anti-TNF agents owing to formation of antidrug antibodies. 8 Levels of antibodies to infliximab [ATI] gradually decreased while trough levels of infliximab [TRI] increased; clinical response was restored in all five included patients. 8 We therefore evaluated in a large multicentre retrospective study, enrolling all consecutive adult patients who started anti-TNF monotherapy for CD in four referral centres, the short-and long-term outcomes of these patients. We also investigated whether starting an immunomodulator among patients losing response to anti-TNF monotherapy could be used for resetting immunogenicity and improving pharmacokinetics without representing a loss of opportunity for these patients.
Methods

Study population
All consecutive adult patients treated between January 1, 2000 and March 16, 2013 in four referral centres (Nancy, Nice, and SaintEtienne [France] and Liège [Belgium] ) with anti-TNF monotherapy [infliximab or adalimumab] as a first-, second-, third-or fourth-line anti-TNF-therapy were included in this retrospective study. Patients receiving episodic anti-TNF treatment were excluded. Short-term efficacy of anti-TNF monotherapy was evaluated at Weeks 4-12 and was classified as no response, partial response, or complete response. Response was judged by the physician, as no clinical score is routinely used in any of the participating centres and as it was a retrospective study. Long-term efficacy was evaluated by recording anti-TNF persistence as well as clinical benefit at last known follow-up. The need for initiating an immunomodulator during follow-up was evaluated. All CD-related surgeries and hospitalisations were collected. All adverse events occurring during follow-up were recorded.
In the subgroup of patients followed at Saint-Etienne University Hospital, TRI and ATI were measured according to routine practice in all patients losing clinical response to infliximab therapy [ 
Statistical analysis
Qualitative variables were given as frequency and percentage. Quantitative variables were calculated as medians with interquartile range [IQR] .
The cumulative incidences of optimising anti-TNF therapy, remaining on anti-TNF therapy and on combination therapy, starting an immunomodulator, and experiencing an adverse event related to the immunomodulator were calculated using the Kaplan-Meier estimator. When possible, the median survival time and its 95% confidence interval [95% CI] were computed.
Potential predictive factors of immunomodulator initiation were first tested by bivariate analyses using the Cox proportional hazards model. Parameters with a p-value less than 0.2 in bivariate analysis were introduced in a multivariate Cox proportional hazards model with backward selection. Results were expressed with hazard ratio and its 95% confidence interval [95% CI]. To investigate predictors of clinical remission after immunomodulatory introduction, uncontrolled disease and partial response were pooled and we used bivariate Cox proportional-hazards model. Univariate analysis was performed to identify independent predictors of clinical remission 
Short-term clinical efficacy of anti-TNF monotherapy
Clinical efficacy as judged by the physician after anti-TNF induction therapy was observed in 94% of patients [complete response 65.7% and partial response 28.4%], and non-primary response in 6% of patients. Figure 3 ]. Conversely, mean ATI level decreased at 6 months from 320 [200-600] to 60 [p = 0.01, Figure 4A ]. For 7 out of 13 patients, the trough level 
Long-term outcome of anti-TNF monotherapy
Discussion
This is the first study investigating the long-term efficacy and safety profile of anti-TNF monotherapy for CD. The SONIC trial clearly demonstrated that combination therapy is superior to anti-TNF monotherapy for maintaining steroid-free clinical remission at 6 months. 4 However, several studies showed that combination therapy is associated with an increased risk of malignancies, particularly an increased risk of lymphoma. 6, 7 Importantly, this risk is known to be mainly driven by concomitant thiopurine use. 6, 7 By contrast, all available studies failed to identify an increased risk of malignancy among IBD patients treated with anti-TNF monotherapy. 6, 7 In this context, some physicians use anti-TNF as monotherapy in IBD patients, as demonstrated in a recent survey conducted among private gastroenterologists in France. 5 Whether starting anti-TNF monotherapy should be considered as an option in clinical practice for CD patients is still a matter of debate.
We found that only 6% of patients were primary non-responders. This is consistent with data from a large observational study assessing the long-term clinical benefit of infliximab in 614 consecutive patients with CD from a single centre during a median follow-up of 55 months and showing that 10.9% of patients were primary non-responders to infliximab. 10 Our data indicate that in the short term, monotherapy with anti-TNF therapy is highly efficacious in CD in a real-life setting.
However, long-term data are needed to further evaluate whether some patients can be treated with anti-TNF therapy without needing a concomitant immunomodulator. We showed that only 15% of patients needed initiation of an immunomodulator during follow-up. Importantly, three-quarters of patients on anti-TNF monotherapy were in clinical remission as judged by the physician at last report, showing that most patients not needing an immunomodulator have long-term clinical benefit. In the overall population, the cumulative probability of having intestinal resection was 24.9% at 5 years and the cumulative probability of having at least one hospitalisation was 19.2% at 5 years. In a recent French observational study of a referral-centre cohort, the cumulative probability of the first CD-related major abdominal surgery was 25.9% at 5 years. 2 In CD, the annual incidence of hospitalisations was 20%. 11 Loss of response is frequent with anti-TNF therapy in IBD.
12,13 Consistently, we found that the cumulative probability of optimising anti-TNF therapy was 58.8% at 5 years. Overall, these findings indicate that starting with anti-TNF monotherapy does not seem to dramatically worsen disease outcomes.
Combination therapy reduces immunogenicity and increases anti-TNF trough levels. 6, 7 This likely contributes to the greater efficacy profile of combination therapy over anti-TNF monotherapy. Starting a concomitant immunomodulator while being on anti-TNF monotherapy is often perceived as a missed opportunity for these patients, as it might be too late to prevent immunogenicity. Preliminary findings suggest that this approach may be used for resetting immunogenicity in IBD patients on anti-TNF monotherapy losing drug response. 8 However, this awaits confirmation in a larger series of patients. In our study, starting azathioprine treatment in case of loss of response to anti-TNF in 13 infliximab-and 5 adalimumab-treated patients induced clinical remission, biomarker remission, and normalisation of anti-TNF trough levels in 55% of patients at 6 months. It is noteworthy that one-quarter of patients starting an immunomodulator after initiation of anti-TNF monotherapy were still on combination therapy and three-quarters of these were in clinical remission at last follow-up. The safety profile of azathioprine, when introduced after start of anti-TNF monotherapy, is consistent with previous reports on thiopurine in IBD. Overall, these results indicate that introduction of an immunomodulator could be considered in clinical practice among patients who lose response to anti-TNF monotherapy, as it may be efficacious in terms of clinical remission and improvement of pharmacokinetics profile.
Interestingly, independent predictors of immunomodulator initiation were anti-TNF type [higher need for immunomodulator initiation for infliximab than for adalimumab] and first-vs second-/third-/fourth-line anti-TNF therapy in multivariate analysis. Recently, two meta-analyses showed that clinical remission rates at 6 months or 1 year were similar with adalimumab monotherapy and with combination therapy in CD. 14, 15 However, all monoclonal antibodies have the potential for immunogenicity. Furthermore, whereas combination therapy with infliximab is known to be more effective than infliximab monotherapy, no SONIC-like trial is available for adalimumab. The fact that first-line anti-TNF therapy was associated with a lower need for combination therapy may only reflect more refractory disease.
Limitations of our study include the retrospective study design and the lack of evaluation of objective signs of inflammation [C-reactive protein and endoscopy] due to missing data. We did not include a control group of patients receiving combination therapy as by definition this would lead to major bias due to uncontrolled study. However, there are several strengths. This is a large cohort of patients with CD [n = 350] treated over a 13-year period; large pharmacokinetics data after introduction of an immunomodulator were available in 18 patients; the mean duration of follow-up was 42 months; and it was a multicentre cohort study. Our findings were confirmed by other groups. 16, 17 In conclusion, an immunomodulator was initiated in 15% of patients with Crohn's disease starting anti-TNF monotherapy. Independent predictors of immunomodulator initiation were infliximab use and second-/third-/fourth-line anti-TNF therapy. Resetting immunogenicity with an immunomodulator was effective in half of patients in a sub-study. Persistence of anti-TNF treatment at 5 years was observed in half of the 297 patients not starting an immumodulator during follow-up. Taken together, our findings indicate that some CD patients could remain on anti-TNF monotherapy in the long term, without representing a missed opportunity for these patients. This might improve the risk-benefit profile of current strategies based on a widespread and earlier use of biologicals in CD patients. Indeed, this may be a way to improve the long-term safety profile of anti-TNF agents by limiting the number of patients being exposed to combination therapy.
